Format

Send to

Choose Destination
BMC Musculoskelet Disord. 2019 Apr 9;20(1):156. doi: 10.1186/s12891-019-2541-0.

Inflammatory biomarkers in patients with sciatica: a systematic review.

Author information

1
Department of Neurology, OLVG, Amsterdam, The Netherlands.
2
Department of Neurology, OLVG, Amsterdam, The Netherlands. bas.termeulen@olvg.nl.
3
Department of Neurology, Zaans Medisch Centrum, Zaandam, The Netherlands. bas.termeulen@olvg.nl.
4
Department of Neurology, Zaans Medisch Centrum, Zaandam, The Netherlands.
5
Department of Health Sciences, VU University, De Boelelaan, 1081, Amsterdam, HV, Netherlands.
6
Department of Epidemiology and Biostatistics and the Amsterdam Movement Sciences Research Institute, Amsterdam UMC, De Boelelaan, 1081, Amsterdam, HV, Netherlands.

Abstract

BACKGROUND:

This systematic review focusses on inflammation as an underlying pathogenic mechanism in sciatica. We addressed two questions in particular: (1) what inflammatory biomarkers have been identified in patients with sciatica in the literature so far? 2) is there an association between the level of inflammatory activity and clinical symptoms?

METHODS:

The search was conducted up to December 19th 2018 in MEDLINE, EMBASE, CENTRAL and Web of Science. The study selection criteria: (1) observational cohort studies, cross-sectional studies and randomized clinical trials (RCT), (2) adult population (≥ 18 years) population with sciatica, (3) concentrations of inflammatory biomarkers measured in serum, cerebrospinal fluid (CSF) or biopsies, and (4) evaluation of clinically relevant outcome measures (pain or functional status). Three reviewers independently selected studies and extracted data regarding the study characteristics and the outcomes. Risk of Bias was evaluated using an adjusted version of the Quality in Prognosis Studies (QUIPS) tool.

RESULTS:

In total 16 articles fulfilled the criteria for inclusion: 7 cross sectional observational studies and 9 prospective cohort studies that included a total of 1212 patients. With regard to question 1) the following markers were identified: interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, IL-21, tumor necrosis factor-α (TNF-α), phospholipase A2, high sensitivity C-reactive protein (hsCRP), C-X-C motif chemokine 5 (CXCM5), CX3CL1, CCL2, epidermal growth factor (EGF), and monocyte chemotactic protein 4 (MCP-4). With regard to question 2) several positive correlations were found in longitudinal studies: a strong positive correlation between inflammatory mediators or byproducts and pain (measured by visual analogue scale, VAS) was found for IL-21 in two studies (r > 0,8), and moderate positive correlations for TNF-a in both serum (r = 0,629) and biopsy (r = 0.65); severe pain (VAS > 4) is associated with increased hsCRP levels among patients with sciatica (adjusted OR = 3.4 (95% CI, 1.1 to 10).

CONCLUSION:

In this systematic review there was considerable heterogeneity in the type of biomarkers and in the clinical measurements in the included studies. Taking into account the overall risk of bias of the included studies there is insufficient evidence to draw firm conclusions regarding the relationship between inflammation and clinical symptoms in patients with sciatica.

KEYWORDS:

Biomarkers; Cytokines; Inflammation; Interleukin; Lumbar disc herniation; Sciatica; Systematic review

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center